Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01139047 · ClinicalTrials.gov registry record · Phase 4
Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin
A Phase 4 study of Skin Manifestations, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 77
- Enrollment target
- 1
- Study location
NCT01139047: Completed Phase 4 study of Skin Manifestations, sponsored by Galderma R&D.
NCT01139047 is a Phase 4 study of Skin Manifestations that has completed, run by Galderma R&D. The registered enrollment target is 77 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01139047, a Phase 4 study of Skin Manifestations, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 77 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the tolerability of MetroGel® 1% to Finacea® 15% in subjects with healthy skin applied according to product labeling for three weeks.
Primary Outcome
Number of participants who were a success with regard to worst post-baseline tolerability scores in each of the tolerability assessments at any time point between baseline and week 3. Tolerability assessments (erythema, scaling, dryness, stinging/burning) are evaluated on a scale from 0 - 4 (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) with 0 being best and 4 being worst. Success was defined as a tolerability score of 0.
Conditions Studied
Interventions
- DRUG metronidazole 1% gel
- DRUG azelaic acid 15% gel
Study Locations (1)
Colorado
- Thomas J. Stephens & Associates, Inc. - Colorado Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2010-06 |
| Est. Completion | 2010-06 |
| Phase | Phase 4 |
What the finished NCT01139047 record still lists
NCT01139047 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Skin Manifestations appearing as the primary indexed condition, and to 2 interventions - of which metronidazole 1% gel is the first listed.
NCT01139047 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT01139047 about?
NCT01139047 is a clinical study titled "Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin". The purpose of this study is to compare the tolerability of MetroGel® 1% to Finacea® 15% in subjects with healthy skin applied according to product labeling for three weeks.
What is the current status of trial NCT01139047?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 77 participants. The study started on 2010-06. Estimated completion is 2010-06.
What conditions does trial NCT01139047 study?
This clinical trial studies the following conditions: Skin Manifestations.
What interventions are being tested in trial NCT01139047?
The interventions under investigation include: metronidazole 1% gel (DRUG), azelaic acid 15% gel (DRUG).
Who is sponsoring clinical trial NCT01139047?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01139047 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Manifestations
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01139047's enrollment target sits among peer trials
77 989th of 2000 higher than 1,008 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia